GRAIL has raised $3.22B across rounds including $300M Series C (May 2018), $390M Series D (Nov 2019), and a $325M post-IPO transaction (Oct 2025) per supplied data. Founded in 2016, GRAIL developed the Galleri multi-cancer early detection blood test using ultra-deep sequencing of cell-free DNA and machine learning. Funding supported large clinical trials, technology scale-up, and regulatory engagement to bring population-scale cancer screening closer to clinical practice. GRAIL aims to enable earlier cancer detection across multiple types to improve patient outcomes.